Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 1
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Effect of Early High-Dose Recombinant Human Erythropoietin on Behavior and Quality of Life in Children Aged 5 Years Born Very Preterm: Secondary Analysis of a Randomized Clinical Trial.
Picotti E, Reinelt T, Koller B, Bucher HU, Rüegger CM, Fauchère JC, Natalucci G; Swiss EPO Neuroprotection Trial Group. Picotti E, et al. JAMA Netw Open. 2022 Dec 1;5(12):e2245499. doi: 10.1001/jamanetworkopen.2022.45499. JAMA Netw Open. 2022. PMID: 36477478 Free PMC article. Clinical Trial.
IMPORTANCE: In light of the promising neuroprotective properties of recombinant human erythropoietin (RHEpo), the Swiss EPO Neuroprotection Trial was started to investigate its effect on neurodevelopment in very preterm infants. ...DESIGN, SETTING, AND …
IMPORTANCE: In light of the promising neuroprotective properties of recombinant human erythropoietin (RHEpo), the Swiss EPO …
Placebo by Proxy in Neonatal Randomized Controlled Trials: Does It Matter?
Burkart TL, Kraus A, Koller B, Natalucci G, Latal B, Fauchère JC, Bucher HU, Rüegger CM; Swiss Epo Neuroprotection Trial Group. Burkart TL, et al. Children (Basel). 2017 May 30;4(6):43. doi: 10.3390/children4060043. Children (Basel). 2017. PMID: 28556820 Free PMC article.
The aim of this study was to investigate whether in a randomized controlled trial (RCT) there is a clinically relevant difference in long-term outcome between very preterm infants whose parents assume that verum (PAV) had been administered and very preterm infants whose pa …
The aim of this study was to investigate whether in a randomized controlled trial (RCT) there is a clinically relevant difference in …
Network based statistics reveals trophic and neuroprotective effect of early high dose erythropoetin on brain connectivity in very preterm infants.
Jakab A, Ruegger C, Bucher HU, Makki M, Huppi PS, Tuura R, Hagmann C; Swiss EPO Neuroprotection Trial Group. Jakab A, et al. Neuroimage Clin. 2019;22:101806. doi: 10.1016/j.nicl.2019.101806. Epub 2019 Apr 1. Neuroimage Clin. 2019. PMID: 30991614 Free PMC article. Clinical Trial.
In this case-control study, connectomic analysis based on diffusion MRI tractography was applied to evaluate the effect of early high-dose EPO in preterm infants. A whole brain, network-level analysis revealed a sub-network of anatomical brain connections in which connecti …
In this case-control study, connectomic analysis based on diffusion MRI tractography was applied to evaluate the effect of early high-dose …
Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial.
Natalucci G, Latal B, Koller B, Rüegger C, Sick B, Held L, Bucher HU, Fauchère JC; Swiss EPO Neuroprotection Trial Group. Natalucci G, et al. JAMA. 2016 May 17;315(19):2079-85. doi: 10.1001/jama.2016.5504. JAMA. 2016. PMID: 27187300 Free article. Clinical Trial.
In an intention-to-treat analysis, mean MDI was not statistically significantly different between the rhEPO group (93.5 [SD, 16.0] [95% CI, 91.2 to 95.8]) and the placebo group (94.5 [SD, 17.8] [95% CI, 90.8 to 98.5]) (difference, -1.0 [95% CI, -4.5 to 2.5]; P = .56 …
In an intention-to-treat analysis, mean MDI was not statistically significantly different between the rhEPO group (93.5 [SD, 16.0] [9 …
Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
Natalucci G, Latal B, Koller B, Rüegger C, Sick B, Held L, Fauchère JC; Swiss EPO Neuroprotection Trial Group. Natalucci G, et al. JAMA. 2020 Dec 8;324(22):2324-2327. doi: 10.1001/jama.2020.19395. JAMA. 2020. PMID: 33289818 Free PMC article. Clinical Trial.
This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks' gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo....
This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks' gestation and randomized at birth to r …